Comparing the current results to its competitors, Lantern Pharma Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 66.26 %, recorded in the same quarter.
Lantern Pharma Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes major pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and both public and private research organizations. Competitors often possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Smaller or early-stage companies may also present competition, particularly through collaborations with larger entities. Industry mergers and acquisitions can concentrate resources among fewer competitors. Competition extends to recruiting qualified personnel, establishing clinical trial sites, patient enrollment, and acquiring complementary technologies. The company's commercial prospects may be affected if competitors develop safer, more effective, or more convenient medicines or obtain regulatory approvals more quickly. Additionally, competition is influenced by insurers and third-party payors promoting generic medicines. Any drug candidates developed by the company will compete with existing and future therapies.
May 5, 2025
: In a pivotal development for the treatment of Triple Negative Breast Cancer (TNBC), Lantern Pharma Inc. (Nasdaq: LTRN), an avant-garde artificial intelligence (AI) driven biotech company, has announced the U.S. Food and Drug Administration s (FDA) clearance of its Investigational New Drug (IND) application for a Phase 1b/2 clinical trial of LP-184. This promising clearance, driven by the company’s proprietary AI platform, RADR, marks a noteworthy advancement in the realm of targeted cancer therapies. The sophisticated integration of AI into drug development processes not only accelerates therapeutic discovery but also enhances precision medicine strategies in oncology. The current market performance of...
November 19, 2024
In an inspiring development for the oncology community, Lantern Pharma Inc. (NASDAQ: LTRN), an emerging leader in targeted cancer therapies powered by artificial intelligence (AI), has announced the dosing of its first patient in Japan as part of the expansion cohort for its Phase 2 HARMONIC clinical trial. This trial critically focuses on LP-300, a novel treatment designed specifically for never-smoker patients afflicted with non-small cell lung cancer (NSCLC) who have demonstrated disease progression following prior treatment with tyrosine kinase inhibitors (TKIs).The significance of this milestone cannot be overstated. As the global healthcare ecosystem continues to innovate in the fight against cancer, L...
August 7, 2024
Harnessing AI Innovation in Oncology: Lantern Pharma s Breakthroughs in Cancer Treatment Synergy and Development In recent developments that promise a transformative impact on oncology drug development, Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company at the forefront of integrating artificial intelligence (AI) and machine learning (ML) into the pharmaceutical landscape, has unveiled compelling preclinical results reflecting the synergy of its investigational drug LP-184 with checkpoint inhibitors. This innovative approach, presented at the esteemed Immuno-Oncology Summit 2024 in Dallas, showcases its potential to re-sensitize tumors that have previously shown resistance to anti...
April 24, 2024
Lantern Pharma Inc., a pioneering artificial intelligence (AI) company revolutionizing cancer therapy development, has recently unveiled an exciting webinar series known as Webinar Wednesdays. This insightful initiative aims to delve into critical areas of oncology drug development by featuring world-class physician scientists and key opinion leaders who are at the forefront of advancements in this field. Leveraging its proprietary RADR AI and machine learning (ML) platform, Lantern Pharma seeks to address pressing challenges in oncology drug research and development, ultimately driving therapies that are both targeted and transformative.Exploring Areas of High Oncology Drug Development Interest:Webinar Wedn...
March 5, 2024
In a powerful move towards revolutionizing cancer drug discovery, Lantern Pharma Inc. (NASDAQ: LTRN) is set to participate in H.C Wainwright and Co. s 1st Annual Artificial Intelligence Based Drug Discovery and Development Virtual Conference. The renowned conference, which will take place on Thursday, March 7th, promises to offer a platform for the discussion and presentation of groundbreaking advancements in the field.Lantern Pharma has positioned itself as a frontrunner in the implementation of artificial intelligence (AI) in cancer drug discovery and development. The company s CEO, Mr. Panna Sharma, will engage in an engaging fireside chat format during the conference to highlight the innovative strides m...
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Lantern Pharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lantern Pharma Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
